Hemab Therapeutics completes $346.7M IPO, gains FDA breakthrough designation for sutacimig

Hemab Therapeutics, a clinical-stage biotech developing blood coagulation therapies, raised $346.7 million in its May 2026 IPO and began trading on Nasdaq under ticker COAG. The company also received FDA Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia, accelerating its path toward pivotal trials.